Builds complete flat panel X-ray detectors from scratch inside a single cleanroom facility.
What stands out
- Revenue is growing, but receivables are growing even faster
At a glance
Builds complete flat panel X-ray detectors from scratch inside a single cleanroom facility.
What this company is and how it runs — written from structure, not news.
Iray Technology deposits amorphous silicon transistor arrays onto glass inside a single cleanroom facility and then bonds those arrays to cesium iodide scintillator material and calibrates them with image-processing software to produce complete X-ray flat panel detectors. Because any flaw introduced during the deposition step cannot be corrected — the array is simply discarded — the number of usable detectors the company can ship in a given period is set almost entirely by how reliably that first step runs, which means the economics of every sale and service contract trace back to yield on the deposition line. Owning both steps under one roof means the quality signal from deposition feeds directly into assembly without the variation that appears when a transistor array crosses between two separate companies, and that structural absence of hand-off variation is what a competitor buying TFT arrays from an outside foundry cannot replicate no matter how much capital they spend. The whole model depends on continued access to the deposition equipment needed to hold and improve that yield, so US-China export controls on advanced semiconductor manufacturing tools represent the sharpest threat — if those controls block machinery upgrades, the integrated-line advantage that makes ownership of both steps valuable begins to erode.
How does this company make money?
The company earns money each time it sells a flat panel X-ray detector to a hospital or a medical equipment manufacturer. It also collects recurring revenue from the detectors already in the field — through calibration services, software updates, and replacement components sold under service contracts tied to installed systems.
What makes this company hard to replace?
Each detector module is calibrated to work with a specific X-ray generator model already installed in a hospital or clinic. Switching to a different detector supplier triggers a requalification process that can take several months. On top of that, existing service contracts with radiology departments are built around detector-specific maintenance protocols, and those contracts would need to be fully renegotiated before a replacement supplier could step in.
What limits this company?
The cleanroom deposition line is the ceiling. Adding capacity means building and qualifying new cleanroom space, sourcing specialized equipment, and training technical staff who understand the exact process recipes that keep yield at medical imaging quality. None of that can be bought or hired quickly, so the company cannot simply spend its way to faster growth.
What does this company depend on?
The company cannot run without amorphous silicon precursor gases for TFT deposition, glass substrates flat enough to meet medical imaging specifications, and cesium iodide scintillator material for X-ray conversion. It also depends on FDA 510(k) clearances to sell devices in the US and NMPA approval to manufacture and sell in China — losing either regulatory status would close those markets entirely.
Who depends on this company?
Hospital radiology departments that already own digital X-ray systems depend on this company for replacement detectors — without them, hospitals would have to replace entire machines rather than a single component. Industrial NDT service providers running automated inspection lines would face equipment downtime if compatible detectors were unavailable. Medical equipment distributors would lose a key product they sell as part of complete digital radiography systems.
How does this company scale?
Once the image-processing software is written and tested, it can be copied onto unlimited detector units at almost no extra cost per unit — that part scales easily. What does not scale easily is the cleanroom itself: every increase in order volume eventually runs into the same wall of facility space, qualification time, and specialized staff that cannot be hired or trained on short notice.
What external forces can significantly affect this company?
US-China export controls on advanced semiconductor manufacturing equipment are the most direct threat, as they could cut off access to the deposition tools the company relies on. Hospital purchasing decisions are tied to healthcare reimbursement policy — when policy changes tighten hospital capital budgets, orders for new digital X-ray equipment slow down and so does demand for detectors. Geopolitical tensions affecting rare earth element supply chains could disrupt the availability of cesium iodide scintillator material, which is essential to every detector the company makes.
Where is this company structurally vulnerable?
US-China export controls on advanced semiconductor manufacturing equipment could block the company from buying the deposition tools it needs to maintain or improve TFT yield. If yield falls, the economics of running an integrated facility stop working, and the one advantage that makes owning both steps worthwhile disappears.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in2 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Two structural conditions align: (1) a multi-year price band exists where the stock has, on at least two separated occasions, stopped declining and bounced upward, and (2) current price is back inside or just above that zone after a meaningful drawdown from peak. The retest is a real one — the stock is not at a new all-time high being measured as a low.
Three observations have aligned: the magnitude of difference between recent (10-week) and long-run (52-week) annualized volatility is high, recent 10-week ATR is above its prior 10-week window, and 20-week annualized volatility is in the upper portion of its mapped range.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
What the company actually pays, and whether its own cash supports it.
The reported statements, read against the company's own industry.
2 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Three observations describe the configuration: operating income margin is elevated, capex intensity (capex / operating cash flow, industry-benchmarked) is high, and EBIT-to-EBITDA is high (small D&A gap). This pattern is consistent with a growing asset base, an asset-light operating profile, or current-period cost capitalization.
Where is this company structurally exposed?
Three price-behavior observations have aligned: the ulcer index (drawdown depth and duration composite) is elevated, current drawdown from peak is significant, and 20-week annualized volatility is in the upper portion of its mapped range.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph